Forbes — A startup aimed at identifying genetic modifiers (genes that impact how other ones are expressed) to develop new drugs launched Thursday with $191 million in funding from investors Third Rock Ventures and ARCH Venture Partners, among others. Maze…
latest press coverage
December 7, 2020
latest media coverage
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
February 28, 2019
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
Xconomy San Francisco — People who share the same disease-causing genetic mutation can have a wide range of severity in their disease. Some don’t get sick at all. Environment can play a role, but with ever-more genetic data available, scientists…
MIT Technology Review: The secret to a new drug could be hiding in your genes
MIT Technology Review — Sickle-cell disease is caused by a one-letter spelling mistake in the hemoglobin gene. But not everyone who inherits the error suffers the worst effects of the blood disease. By 2008, scientists had figured out why. It’s…